^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
Ontak is a CD25-directed cytotoxin indicated for the treatment of adult patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients

Excerpt:
...- Interleukin-2 receptor (IL-2R) expression on at least 20% of tumor cells as determined by immunohistochemistry....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

Excerpt:
...- Patient must have been previously enrolled in Protocol 93-04-11 and randomized to the placebo arm; or the patient met all eligibility criteria for protocol 93-04-11 other than the expression of CD25 on CTCL tumor cells....
Trial ID:
Less C2 evidence
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Phase 2 study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma

Published date:
03/31/2021
Excerpt:
Among the 36 patients with PTCL and CTCL, objective response rate based on the independent review was 36% (41% in PTCL, and 31% in CTCL). The median progression-free survival was 3.1 months (2.1 months in PTCL and 4.2 months in CTCL). Our results indicated that a 9 µg/kg/day dose of E7777 shows efficacy and a manageable safety profile in Japanese patients with relapsed or refractory PTCL and CTCL, with clinical activity observed across the range of CD25 expression.
DOI:
10.1111/cas.14906